ACTHAR Therapy for Central Nervous System Sarcoidosis

Withdrawn before enrolling · Phase 4

Conditions studied: Sarcoidosis

In brief

There is a need for a more reliable, expeditious therapy that can be used as an alternative to glucocorticoids in severe Central Nervous System (CNS) sarcoidosis. This study aims to provide evidence for effectiveness of ACTHAR gel in CNS sarcoidosis, and provide information about its safety and tolerability

Key facts

Study ID

NCT02920710

Run by

The Cleveland Clinic

People needed

0

Starts

2019-02-01

Expected to finish

2020-11-02

Last updated by the study team

2020-11-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with sarcoidosis as defined by ATS/ERS/WASOG (American Thoracic Society/European Thoracic Society/World Association for Sarcoidosis and Other Granulomatous Disorders)
• Stable baseline immunosuppressive medications
• Moderate to severe disease as defined by at least one of the following criteria:
• Cranial nerve palsy
• Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement
• Dural or leptomeningeal involvement of brain and/or spinal cord
• Hydrocephalus
• Seizures

You may not qualify if…

• Diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results
• Significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months
• Evidence of current serious infection, or a history of chronic or recurring infections.
• Contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar).
• Allergies to pig-derived proteins
• Have a history of any opportunistic infection within 6 months prior to screening
• History of malignancy.

Where it is running

• Cleveland Clinic Main Campus — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.